Akebia Therapeutics (Germany) Performance
| AX9 Stock | 1.93 0.02 1.05% |
On a scale of 0 to 100, Akebia Therapeutics holds a performance score of 14. The firm shows a Beta (market volatility) of 0.0349, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Akebia Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Akebia Therapeutics is expected to be smaller as well. Please check Akebia Therapeutics' treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to make a quick decision on whether Akebia Therapeutics' price patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Akebia Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Akebia Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 231.1 M | |
| Free Cash Flow | -253 M |
Akebia |
Akebia Therapeutics Relative Risk vs. Return Landscape
If you would invest 126.00 in Akebia Therapeutics on September 3, 2024 and sell it today you would earn a total of 67.00 from holding Akebia Therapeutics or generate 53.17% return on investment over 90 days. Akebia Therapeutics is generating 0.7314% of daily returns and assumes 3.9474% volatility on return distribution over the 90 days horizon. Simply put, 35% of stocks are less volatile than Akebia, and 86% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Akebia Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Akebia Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Akebia Therapeutics, and traders can use it to determine the average amount a Akebia Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1853
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AX9 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.95 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.73 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 14 86% of assets perform better |
Based on monthly moving average Akebia Therapeutics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akebia Therapeutics by adding it to a well-diversified portfolio.
Akebia Therapeutics Fundamentals Growth
Akebia Stock prices reflect investors' perceptions of the future prospects and financial health of Akebia Therapeutics, and Akebia Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Akebia Stock performance.
| Current Valuation | 12.46 M | |||
| Price To Book | 3.97 X | |||
| Price To Sales | 0.18 X | |||
| Revenue | 213.58 M | |||
| EBITDA | (227.35 M) | |||
| Cash Flow From Operations | (252.97 M) | |||
| Total Asset | 525.55 M | |||
About Akebia Therapeutics Performance
Assessing Akebia Therapeutics' fundamental ratios provides investors with valuable insights into Akebia Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Akebia Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Akebia Therapeutics performance evaluation
Checking the ongoing alerts about Akebia Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Akebia Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Akebia Therapeutics may become a speculative penny stock | |
| Akebia Therapeutics appears to be risky and price may revert if volatility continues | |
| Akebia Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 213.58 M. Net Loss for the year was (282.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Akebia Therapeutics generates negative cash flow from operations |
- Analyzing Akebia Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Akebia Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Akebia Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Akebia Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Akebia Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Akebia Therapeutics' stock. These opinions can provide insight into Akebia Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Akebia Stock Analysis
When running Akebia Therapeutics' price analysis, check to measure Akebia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Therapeutics is operating at the current time. Most of Akebia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akebia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Therapeutics' price. Additionally, you may evaluate how the addition of Akebia Therapeutics to your portfolios can decrease your overall portfolio volatility.